Secreted ERBB3 isoform p85 has been shown to inhibit the action of its ligand Neuregulin [98, 107], nuclear translocations act as co-transcriptional activators [108], possible post-translation modification and the tumour microenvironment are instructive to serum ERBB3 secretion from the cell [96] and functions yet to be determined. Here, ERBB3 is linked to neoplasm.